Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 8/20 | 0.37 |
| ▸ | USP2 | O75604 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409773 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP2D6CASP1USP2SYK | |
| SCHEMBL1408967 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP2D6CASP1USP2SYK | |
| SCHEMBL13139841 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP2D6CASP1USP2SYK | |
| SCHEMBL7344489 | 0.83 | CYP2D6 (0.43) | SMN1; SMN2CYP2D6CASP1HDAC3HDAC1 | |
| SCHEMBL1409667 | 0.83 | CYP2D6 (0.43) | SMN1; SMN2CYP2D6CASP1HDAC3HDAC1 | |
| SCHEMBL29990821 | 0.82 | CYP2D6 (0.55) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3689498 | 0.82 | CYP2D6 (0.55) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL344731 | 0.82 | CYP2D6 (0.55) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL168389 | 0.82 | CYP2D6 (0.55) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8764106 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP2D6CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691848-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2261234-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261235-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261233-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261232-A2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| EP-2011800-A2 | Inhibitors of caspase | Vertex Pharmaceuticals Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1064298-B1 | INHIBITORS OF CASPASES | VERTEX PHARMA (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-20030232986-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| EP-0519748-B1 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO INC (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0648128-A4 | DNA ENCODING PRECURSOR INTERLEUKIN 1-g(b) CONVERTING ENZYME. | MERCK & CO INC (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5434248-A | Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0648128-A1 | DNA ENCODING PRECURSOR INTERLEUKIN 1$g(b) CONVERTING ENZYME | MERCK & CO. INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994006906-A1 | DNA ENCODING MURINE PRECURSOR INTERLEUKIN 1β CONVERTING ENZYME | MERCK & CO., INC. (US) | 1994-03-31 | — | — | WO | disclosed |
| US-5278061-A | Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1994-01-11 | — | — | US | disclosed |
| WO-1994000154-A1 | DNA ENCODING PRECURSOR INTERLEUKIN 1β CONVERTING ENZYME | MERCK & CO., INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0533350-A1 | DNA encoding precursor interleukin 1B converting enzyme | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0529713-A1 | Affinity chromatography matrix useful in purifying interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1993-03-03 | — | — | EP | disclosed |
| EP-0519748-A2 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048226-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | SMN1; SMN2 3471/4885CYP2D6 3358/4885CASP1 1/4885 |
| US-20030232986-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | SMN1; SMN2 3133/4885CYP2D6 3197/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.